Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -952,000 | 456,000 | 608,000 | 306,000 | 84,000 |
| Depreciation Amortization | 323,000 | 1,330,000 | 1,010,000 | 681,000 | 376,000 |
| Income taxes - deferred | -175,000 | -120,000 | 13,000 | 5,000 | -11,000 |
| Other Working Capital | 559,000 | -1,701,000 | -1,881,000 | -1,679,000 | -1,076,000 |
| Other Operating Activity | 196,000 | 833,000 | 592,000 | 500,000 | 222,000 |
| Operating Cash Flow | $-49,000 | $798,000 | $342,000 | $-187,000 | $-405,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -132,000 | -251,000 | -140,000 | -9,000 | -12,000 |
| Net Acquisitions | -7,000 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -4,000 | -47,000 | -36,000 | -36,000 | -2,000 |
| Sale Of Investment | N/A | 172,000 | 172,000 | 153,000 | 46,000 |
| Other Investing Activity | 304,000 | 1,649,000 | 1,281,000 | 881,000 | 476,000 |
| Investing Cash Flow | $161,000 | $1,523,000 | $1,277,000 | $989,000 | $508,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 700,000 | 500,000 | N/A | N/A |
| Debt Issued | N/A | 4,974,000 | N/A | N/A | N/A |
| Debt Repayment | N/A | -7,140,000 | -1,966,000 | -491,000 | -491,000 |
| Other Financing Activity | 2,000 | -706,000 | -205,000 | -3,000 | -2,000 |
| Financing Cash Flow | $2,000 | $-2,172,000 | $-1,671,000 | $-494,000 | $-493,000 |
| Exchange Rate Effect | -62,000 | -128,000 | -80,000 | -49,000 | -44,000 |
| Beginning Cash Position | 2,198,000 | 2,177,000 | 2,177,000 | 2,177,000 | 2,177,000 |
| End Cash Position | 2,250,000 | 2,198,000 | 2,045,000 | 2,436,000 | 1,743,000 |
| Net Cash Flow | $52,000 | $21,000 | $-132,000 | $259,000 | $-434,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | -49,000 | 798,000 | 342,000 | -187,000 | -405,000 |
| Capital Expenditure | -157,000 | -562,000 | -409,000 | -263,000 | -150,000 |
| Free Cash Flow | -206,000 | 236,000 | -67,000 | -450,000 | -555,000 |